Market Overview

The global artificial intelligence in life sciences market was valued at USD 2.9 Billion in 2024 and is expected to reach USD 16.7 Billion by 2033, exhibiting a CAGR of 21.5% during the forecast period of 2025-2033. The market growth is driven by factors such as the rising prevalence of complex diseases and the integration of AI in genomics research, medical imaging analysis, and other emerging technologies.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Artificial Intelligence in Life Sciences Market Key Takeaways

• Current Market Size: USD 2.9 Billion in 2024
• CAGR: 21.5%
• Forecast Period: 2025-2033
• The market growth is propelled by the increasing volume of biomedical data from genomic sequences and electronic health records requiring advanced AI tools.
• AI considerably accelerates drug discovery and development, reducing time and costs.
• Cloud computing and Internet of Things (IoT) integration enhance AI data accessibility and real-time analysis.
• North America dominates the market due to advanced infrastructure, substantial investment, and regulatory support.
• Ethical AI and transparent algorithms are gaining importance to ensure data security and privacy compliance.
• Drug discovery represents the largest application segment within the market.

Sample Request Link: https://www.imarcgroup.com/artificial-intelligence-in-life-sciences-market/requestsample

Market Growth Factors

Artificial intelligence in life sciences is mainly fueled by the surge in biomedical data from genomic sequences and electronic health records. This vast and complex data volume necessitates the deployment of robust AI tools to enable effective data management and advanced analysis. These AI systems enhance decision-making capabilities, particularly in deciphering genomics, proteomics, and clinical datasets, helping researchers uncover critical insights that propel innovation in healthcare solutions.

AI's instrumental role in accelerating drug discovery and development is a major driver of market expansion. By significantly reducing the time and cost required in these processes, AI facilitates faster identification of drug candidates, optimizes their properties, and predicts efficacy and safety profiles early in the development pipeline. These capabilities mitigate the risks of late-stage failures, streamline the pharmaceutical pipeline, and promote cost efficiency.

The integration of advanced computational algorithms and regulatory support further supports AI adoption in clinical settings. Advancements in machine learning techniques enable AI systems to analyze diverse, large-scale datasets with increasing accuracy. Regulatory bodies are recognizing the benefits of AI applications and are providing clearer guidelines for integration, thereby encouraging investment and innovation in AI technologies in life sciences.

Market Growth Factors

One of the key trends driving growth in artificial intelligence within life sciences is its integration with cloud computing and Internet of Things (IoT) devices. This enables real-time data accessibility and analysis across geographically dispersed research and clinical teams. Cloud-based AI platforms offer scalability and flexibility while minimizing upfront infrastructure costs, making AI technology accessible to a broader range of organizations, including research institutions and healthcare providers.

AI-driven predictive models are another significant trend enhancing clinical decision-making. These models utilize machine learning to forecast disease progression and patient outcomes, which aids in timely interventions and personalized treatment plans. Collaborations between AI technology firms and pharmaceutical companies are increasing, focusing on refining AI applications for drug development, patient monitoring, and clinical trials, further driving market maturity.

The growing emphasis on ethical AI and transparent algorithms addresses rising concerns around patient data privacy and security. This focus ensures compliance with regulatory frameworks and builds trust among stakeholders, fostering wider AI adoption. Additionally, AI-powered robotic process automation (RPA) streamlines administrative tasks in healthcare, improving operational efficiency and reducing human error.

Market Growth Factors

Geographically, North America leads the artificial intelligence in life sciences market due to its established technological infrastructure and substantial investments in AI research and healthcare. Government initiatives, private sector funding, and venture capital investments flow heavily into AI development projects, accelerating innovation across AI-driven drug discovery, genomics, healthcare analytics, and personalized medicine.

North America's regulatory framework promotes innovation by providing clear guidelines and approval processes for AI-based medical devices and treatments, encouraging commercial investment. The region's advanced healthcare infrastructure, including extensive electronic health record systems and a large patient population, offers a conducive environment for AI solution testing and implementation.

Furthermore, emerging markets, particularly in Asia Pacific, are experiencing rapid growth driven by increasing healthcare demands, government initiatives, and technological advancements. These regions present significant opportunities for AI applications to bridge healthcare service gaps, indicating robust potential for market expansion beyond traditionally dominant regions.

Market Segmentation

Breakup by Offering:

• Software: Dominates the market; includes AI tools and platforms for processing and analyzing complex data in life sciences research, offering scalability and adaptability for various research needs.
• Hardware: Not further described in source.
• Services: Not further described in source.

Breakup by Deployment:

• On-premises: Not further described in source.
• Cloud-based: Dominates the market; offers scalability, flexibility, cost-effectiveness, and accessibility, enabling collaboration and real-time data analysis without significant upfront investments.

Breakup by Application:

• Drug Discovery: Largest market segment; AI expedites stages of drug development by identifying candidates, predicting efficacy, and optimizing properties, thereby reducing costs and time.
• Medical Diagnosis: Not further described in source.
• Biotechnology: Not further described in source.
• Clinical Trials: Not further described in source.
• Precision and Personalized Medicine: Not further described in source.
• Patient Monitoring: Not further described in source.

Regional Insights

North America dominates the artificial intelligence in life sciences market, driven by advanced technological infrastructure, significant investments in AI research, and strong regulatory support. The region benefits from robust government initiatives, private sector funding, and venture capital inflows that accelerate growth in AI applications across drug discovery, healthcare analytics, and personalized medicine. North America's established healthcare infrastructure and regulatory clarity create an ideal environment for AI innovation and commercialization.

Recent Developments & News

In 2024, Atomwise's AIMS initiative demonstrated the success of its AtomNet AI Platform by discovering novel chemical matter for 235 out of 318 targets, showcasing its broad applicability and potential as an alternative to high-throughput screening in drug discovery. Also in 2024, IBM partnered with the Government of Canada and Quebec to invest approximately CAD 187 million to advance semiconductor chip packaging capabilities and boost R&D at IBM Canada's Bromont plant. This investment aims to strengthen supply chains, create high-paying jobs, and position Canada as a leader in semiconductor innovation.

Key Players

• AiCure LLC
• Apixio Inc. (Centene Corporation)
• Atomwise Inc
• Enlitic Inc.
• International Business Machines Corporation
• Insilico Medicine Inc.
• Nuance Communications Inc.
• NuMedii Inc.
• Sensely Inc.
• Sophia Genetics SA

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

👉Get Custom Market Research for Your Business👈

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302